EICHORCondition: Colorectal Cancer · Pancreatic Ductal Adenocarcinoma · Biliary Tract Cancer · Sponsor: Merck Sharp & Dohme LLC
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the body), or unresectable (the cancer cannot be removed with surgery). The goals of this study are to learn: * About the safety of sacituzumab tirumotecan alone or with other treatments and if people tolerate it * How many people have the cancer respond (get smaller or go away) to treatment
This description comes directly from the study's public registry record.
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has one of the following cancers: * Unresectable or metastatic colorectal cancer and has received prior therapy for the cancer * Advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) and has received prior therapy for the cancer * Advanced and/or unresectable biliary tract cancer (BTC) and has received prior therapy for the cancer * Advanced and/or unresectable BTC and has not received prior therapy for the cancer * For participants who have received prior therapy for cancer: Has recovered from any side effects due to previous cancer treatment Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * History of severe eye disease * For participants who have received prior therapy for cancer: Received prior systemic anticancer therapy including investigational agents within 4 weeks before starting study intervention * History of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids, has current pneumonitis/ILD, or has suspected ILD or pneumonitis that cannot be ruled out by standard diagnostic assessments at Screening
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| UCLA ( Site 0317) | Los Angeles, California, United States | Recruiting |
| University of Colorado Anschutz Medical Campus ( Site 0299) | Aurora, Colorado, United States | Recruiting |
| University of Colorado Anschutz Medical Campus ( Site 0325) | Aurora, Colorado, United States | Recruiting |
| University of Colorado Anschutz Medical Campus ( Site 0326) | Aurora, Colorado, United States | Recruiting |
| Sibley Memorial Hospital ( Site 0310) | Washington D.C., District of Columbia, United States | Recruiting |
| University of Florida College of Medicine ( Site 0281) | Gainesville, Florida, United States | Recruiting |
| Mount Sinai Cancer Center ( Site 0287) | Miami Beach, Florida, United States | Recruiting |
| Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0303) | Marietta, Georgia, United States | Completed |
| Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0327) | Mineola, New York, United States | Recruiting |
| Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 0324) | New York, New York, United States | Recruiting |
| University of Texas MD Anderson Cancer Center ( Site 0316) | Houston, Texas, United States | Recruiting |
| Oncology and Hematology Associates of Southwest Virginia (BRCC) ( Site 0295) | Roanoke, Virginia, United States | Recruiting |
+ 43 more locations — full list on the registry record.
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06428409